ArticleAmerican journal of translational research2025
Efficacy and safety of combined Linggui Bafa Tui Na and Fuxiong San herbal powder therapy in pediatric Mycoplasma pneumonia.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of combining Linggui Bafa Tui Na with Fuxiong San in the treatment of pediatric Mycoplasma pneumonia (MP).
methodsThis retrospective study included 110 children diagnosed with MP at the East Campus of Zhengzhou Children's Hospital between January 2022 and January 2025. Participants were divided into two groups according to treatment regimen: the control group (n = 54) received Linggui Bafa Tui Na alone, while the observation group (n = 56) received combined Linggui Bafa Tui Na and Fuxiong San pasting therapy. Primary outcomes included clinical cure rate, pulmonary function parameters (forced expiratory volume in one second [FEV
resultsCompared with the control group, the observation group showed greater reductions in inflammatory markers - WBC count (8.5 ± 1.2 → 6.3 ± 0.9, P < 0.001), neutrophil count (4.2 ± 0.8 → 2.9 ± 0.6, P < 0.001), and PCT (0.98 ± 0.12 → 0.47 ± 0.08, P < 0.001) - and more pronounced improvements in pulmonary - FEV
conclusionThe combination of Linggui Bafa Tui Na and Fuxiong San pasting therapy provides superior efficacy and safety over Linggui Bafa Tui Na alone for pediatric MP, improving clinical outcomes and reducing adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.